30 unchanged sentences
The following table provides certain information regarding our equity compensation plans in effect as of December 31, 2025:
−Removed: Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
−Removed: Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights
+Added: Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights
+Added: Weighted-Average Exercise Price of Outstanding Options and Rights
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans
25 unchanged sentences
Indenture, dated as of August 14, 2020, between Omeros Corporation and Wells Fargo Bank, National Association, as trustee
−Removed: First Supplemental Indenture, dated as of August 14, 2020, between Omeros Corporation and Wells Fargo Bank, National Association, as trustee (including the form of 5.25% Convertible Senior Notes due 2026)
+Added: Second Supplemental Indenture, dated as of May 14, 2025, between the Company and Computershare Trust Company, National Association, as trustee (including the form of 9.50% Convertible Senior Notes due 2029)
Form of Indemnification Agreement entered into between Omeros Corporation and its directors and officers
31 unchanged sentences
2 to License Agreement with an effective date of January 25, 2013 between Omeros Corporation and Daiichi Sankyo Co., Ltd.
−Removed: Form of capped call transaction confirmation, in reference to the 5.25% Convertible Senior Notes due 2026
Combined Development and Commercial Supply Agreement, effective as of May 16, 2018, between Omeros Corporation and Vetter Pharma international GmbH
Master Services Agreement, dated July 28, 2019, between Omeros Corporation and Lonza Biologics Tuas Pte.
−Removed: Technology License Agreement, effective August 28, 2020 between Omeros Corporation and Xencor, Inc.
Asset Purchase Agreement, dated as of December 1, 2021 among Omeros Corporation, Rayner Surgical Inc.
1 unchanged sentence
Amended and Restated Royalty Purchase Agreement between Omeros Corporation and DRI Healthcare Acquisitions LP dated February 1, 2024
−Removed: Credit and Guaranty Agreement, dated as of June 3, 2024, among Omeros Corporation, certain subsidiaries of Omeros Corporation, as guarantors, various Lenders and Wilmington Savings Fund Society, FSB, as Administrative Agent and Collateral Agent
−Removed: Pledge and Security Agreement, dated as of June 3, 2024, between Omeros Corporation, nura inc.
−Removed: and Wilmington Savings Fund Society, FSB, as Collateral Agent
+Added: Asset Purchase and License Agreement, dated as of October 10, 2025, between Omeros Corporation and Novo Nordisk Health Care AG
Omeros Corporation Insider Trading Policy
15 unchanged sentences
Indicates management contract or compensatory plan or arrangement.
−Removed: Certain identified information has been excluded from the exhibit because it both (A) is not material and (B) would be competitively harmful if publicly disclosed.
+Added: Certain identified information has been excluded from the exhibit because it both (A) is not material and (B) is the type that the registrant treats as private or confidential.
FORM 10-K SUMMARY
35 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.